These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21575258)

  • 41. Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.
    Mercier PL; Bachvarova M; Plante M; Gregoire J; Renaud MC; Ghani K; Têtu B; Bairati I; Bachvarov D
    Mol Oncol; 2011 Oct; 5(5):438-53. PubMed ID: 21856257
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relationship between RAS Association Domain Family Protein 1A Promoter Methylation and the Clinicopathological Characteristics in Patients with Ovarian Cancer: A Systematic Meta-Analysis.
    Wang H; Cui M; Zhang S; He J; Song L; Chen Y
    Gynecol Obstet Invest; 2018; 83(4):349-357. PubMed ID: 29130987
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma.
    Ho CM; Huang CJ; Huang CY; Wu YY; Chang SF; Cheng WF
    Mol Cancer; 2012 Aug; 11():53. PubMed ID: 22871047
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aberrant promoter methylation of SPARC in ovarian cancer.
    Socha MJ; Said N; Dai Y; Kwong J; Ramalingam P; Trieu V; Desai N; Mok SC; Motamed K
    Neoplasia; 2009 Feb; 11(2):126-35. PubMed ID: 19177197
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MicroRNA-802 plays a tumour suppressive role in tongue squamous cell carcinoma through directly targeting MAP2K4.
    Wu X; Gong Z; Sun L; Ma L; Wang Q
    Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28319306
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Integrative prediction of gene function and platinum-free survival from genomic and epigenetic features in ovarian cancer.
    Wrzeszczynski KO; Varadan V; Kamalakaran S; Levine DA; Dimitrova N; Lucito R
    Methods Mol Biol; 2013; 1049():35-51. PubMed ID: 23913207
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Hypermethylation of fragile histidine triad gene and 3p14 allelic deletion in ovarian carcinomas].
    Hong FZ; Wang B; Li HM; Liew CT
    Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):257-61. PubMed ID: 16181544
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course.
    Xin W; Yun KJ; Ricci F; Zahurak M; Qiu W; Su GH; Yeo CJ; Hruban RH; Kern SE; Iacobuzio-Donahue CA
    Clin Cancer Res; 2004 Dec; 10(24):8516-20. PubMed ID: 15623633
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MicroRNA-27a promotes proliferation, migration and invasion by targeting MAP2K4 in human osteosarcoma cells.
    Pan W; Wang H; Jianwei R; Ye Z
    Cell Physiol Biochem; 2014; 33(2):402-12. PubMed ID: 24556602
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hypo/unmethylated promoter status of Cdk2 gene correlates with its over-expression in ovarian cancer in north Indian population.
    Kanwal A; Kaur M; Singh A; Gupta S; Sachan M
    Cell Mol Biol (Noisy-le-grand); 2016 Jan; 62(1):67-72. PubMed ID: 26828990
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
    Ruscito I; Dimitrova D; Vasconcelos I; Gellhaus K; Schwachula T; Bellati F; Zeillinger R; Benedetti-Panici P; Vergote I; Mahner S; Cacsire-Tong D; Concin N; Darb-Esfahani S; Lambrechts S; Sehouli J; Olek S; Braicu EI
    Eur J Cancer; 2014 Aug; 50(12):2090-8. PubMed ID: 24889916
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.
    Engler DA; Gupta S; Growdon WB; Drapkin RI; Nitta M; Sergent PA; Allred SF; Gross J; Deavers MT; Kuo WL; Karlan BY; Rueda BR; Orsulic S; Gershenson DM; Birrer MJ; Gray JW; Mohapatra G
    PLoS One; 2012; 7(2):e30996. PubMed ID: 22355333
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma.
    Wang Y; Kringen P; Kristensen GB; Holm R; Baekelandt MM; Olivier M; Skomedal H; Hainaut P; Tropé CG; Abeler VM; Nesland JM; Børresen-Dale AL; Helland A
    Hum Mutat; 2004 Jul; 24(1):21-34. PubMed ID: 15221786
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
    Bernards SS; Pennington KP; Harrell MI; Agnew KJ; Garcia RL; Norquist BM; Swisher EM
    Gynecol Oncol; 2018 Feb; 148(2):281-285. PubMed ID: 29233532
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival.
    Zhou F; Tao G; Chen X; Xie W; Liu M; Cao X
    Clin Chem Lab Med; 2014 May; 52(5):735-42. PubMed ID: 24327526
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
    Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
    Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
    S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation.
    Pradhan M; Risberg BA; Tropé CG; van de Rijn M; Gilks CB; Lee CH
    BMC Cancer; 2010 Sep; 10():493. PubMed ID: 20843305
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Theoretical proposal: allele dosage of MAP2K4/MKK4 could rationalize frequent 17p loss in diverse human cancers.
    Cunningham SC; Gallmeier E; Hucl T; Dezentje DA; Abdelmohsen K; Gorospe M; Kern SE
    Cell Cycle; 2006 May; 5(10):1090-3. PubMed ID: 16721048
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of mutation and expression of PTEN gene mRNA on tumorigenesis and progression of epithelial ovarian cancer.
    Chen Y; Zheng H; Yang X; Sun L; Xin Y
    Chin Med Sci J; 2004 Mar; 19(1):25-30. PubMed ID: 15104221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.